Tang Prize Award Laureate to Present on CRISPR Technology at 2018 Experimental Biology Meeting

By | February 1, 2018

Experimental Biology is renowned as one of the largest conferences focusing on the life sciences. Hosted by five FASEB member societies – The American Association of Anatomists, The American Physiological Society, The American Society for Biochemistry and Molecular Biology, The American Society for Investigative Pathology, and The American Society for Pharmacology and Experimental Therapeutics – the five-day meeting offers multidisciplinary programming in those scientific fields.

This year’s conference will feature a special presentation from Feng Zhang, PhD, a recipient along with Emmanuelle Charpentier and Jennifer A. Doudna of the 2016 Tang Prize for Biopharmaceutical Science for their work in CRISPR technology. Launched in 2012, the Tang Prize is awarded to laureates on the basis of the originality of their work along with their contributions to society.

Dr. Zhang is an associate professor and investigator at McGovern Institute for Brain Research, both at MIT, and Core Member of the Broad Institute of MIT and Harvard. He is credited for the first adaptation and demonstration of CRISPR technology in mammalian cells. During his presentation, Dr. Zhang will discuss his team’s groundbreaking development of the CRISP/Cas9 genome editing platform, and its promise to revolutionize biomedical research and disease treatment.

EB 2018 will be held April 21-25 in San Diego; early bird registration rates are available through February 27. Additional information on Dr. Zhang’s presentation, which will kick of the meeting, and the many other workshops, poster sessions, and exhibits to follow, can be found at the Experimental Biology website.